These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17712633)

  • 21. CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia.
    Semaan A; Dietrich D; Bergheim D; Dietrich J; Kalff JC; Branchi V; Matthaei H; Kristiansen G; Fischer HP; Goltz D
    Virchows Arch; 2017 Feb; 470(2):185-196. PubMed ID: 27913861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy.
    Schmidt N; Neumann-Haefelin C; Thimme R
    Dig Dis; 2012; 30(5):483-91. PubMed ID: 23108304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potentiality of immunotherapy against hepatocellular carcinoma.
    Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
    World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is there a role for immunotherapy in hepatocellular carcinoma?
    Zerbini A; Pilli M; Ferrari C; Missale G
    Dig Liver Dis; 2006 Apr; 38(4):221-5. PubMed ID: 16461021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine.
    Ren W; Strube R; Zhang X; Chen SY; Huang XF
    Cancer Res; 2004 Sep; 64(18):6645-51. PubMed ID: 15374979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical research on dendritic cell vaccines to prevent postoperative recurrence and metastasis of liver cancer.
    Sun TY; Yan W; Yang CM; Zhang LF; Tang HL; Chen Y; Hu HX; Wei X
    Genet Mol Res; 2015 Dec; 14(4):16222-32. PubMed ID: 26662415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety.
    Nakamoto Y; Mizukoshi E; Tsuji H; Sakai Y; Kitahara M; Arai K; Yamashita T; Yokoyama K; Mukaida N; Matsushima K; Matsui O; Kaneko S
    Clin Exp Immunol; 2007 Feb; 147(2):296-305. PubMed ID: 17223971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients.
    Pan K; Li YQ; Wang W; Xu L; Zhang YJ; Zheng HX; Zhao JJ; Qiu HJ; Weng DS; Li JJ; Wang QJ; Huang LX; He J; Chen SP; Ke ML; Wu PH; Chen MS; Li SP; Xia JC; Zeng YX
    Ann Surg Oncol; 2013 Dec; 20(13):4305-11. PubMed ID: 23892527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
    Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
    Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
    Harding JJ; El Dika I; Abou-Alfa GK
    Cancer; 2016 Feb; 122(3):367-77. PubMed ID: 26540029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perspectives of immunotherapy in hepatocellular carcinoma (HCC).
    Büttner N; Schmidt N; Thimme R
    Z Gastroenterol; 2016 Dec; 54(12):1334-1342. PubMed ID: 27936483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The yin and yang of evasion and immune activation in HCC.
    Makarova-Rusher OV; Medina-Echeverz J; Duffy AG; Greten TF
    J Hepatol; 2015 Jun; 62(6):1420-9. PubMed ID: 25733155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice.
    Li SQ; Lin J; Qi CY; Fu SJ; Xiao WK; Peng BG; Liang LJ
    Hepatogastroenterology; 2014; 61(130):278-84. PubMed ID: 24901124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pre- and post- operative adjuvant targeting locoregional chemotherapy combined with locoregional targeting immunostimulation and surgical resection for hepatocellular carcinoma. A new promising alternative.
    Lygidakis NJ; Konstantinidou T; Pothoulakis J
    Anticancer Res; 1994; 14(3B):1351-5. PubMed ID: 8067704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges in cancer vaccine development for hepatocellular carcinoma.
    Buonaguro L; Petrizzo A; Tagliamonte M; Tornesello ML; Buonaguro FM
    J Hepatol; 2013 Oct; 59(4):897-903. PubMed ID: 23714157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma.
    Cicinnati VR; Zhang X; Yu Z; Ferencik S; Schmitz KJ; Dworacki G; Kaczmarek E; Oldhafer K; Frilling A; Baba HA; Schmid KW; Grosse-Wilde H; Broelsch CE; DeLeo AB; Gerken G; Beckebaum S
    Int J Cancer; 2006 Dec; 119(12):2851-60. PubMed ID: 16998881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells.
    Yang JY; Cao DY; Xue Y; Yu ZC; Liu WC
    Hum Immunol; 2010 Mar; 71(3):255-62. PubMed ID: 20036295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study.
    Lygidakis NJ; Pothoulakis J; Konstantinidou AE; Spanos H
    Anticancer Res; 1995; 15(2):543-50. PubMed ID: 7539237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteomic-based approach for the identification of tumor markers associated with hepatocellular carcinoma.
    Shalhoub P; Kern S; Girard S; Beretta L
    Dis Markers; 2001; 17(4):217-23. PubMed ID: 11790889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combinatorial immunotherapy strategies for hepatocellular carcinoma.
    Tagliamonte M; Petrizzo A; Tornesello ML; Ciliberto G; Buonaguro FM; Buonaguro L
    Curr Opin Immunol; 2016 Apr; 39():103-13. PubMed ID: 26851637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.